|
Market Closed -
Euronext Amsterdam
11:55:00 2026-09-30 EDT
|
5-day change | 1st Jan Change | ||
| 0.8872 EUR | +0.11% |
|
-5.74% | -37.78% |
| 09-13 | Pharming Group Obtains US FDA Nod for Rare Primary Immunodeficiency Drug Joenja | MT |
| 09-11 | Pharming Receives Fda Approval for Joenja as First Treatment for Children with Apds in the U S | CI |
| Market Cap | 713M 628M 595M 537M 1.01B 68.37B 1.03B 7.12B 2.74B 34.95B 2.68B 2.62B 112B | P/E 2026 * |
32.3x | P/E 2027 * | 24x |
|---|---|---|---|---|---|
| Enterprise Value | 666M 587M 556M 502M 946M 63.9B 958M 6.65B 2.56B 32.66B 2.5B 2.45B 105B | EV / Sales 2026 * |
1.74x | EV / Sales 2027 * | 1.56x |
| Free-Float |
98.05% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Euronext Amsterdam
| PHARM | Real-time | |
CBOE
| PHARM | Real-time | |
|
Tradegate
| PHGN | Real-time | |
|
Börse Stuttgart
| PHGN | Delayed | |
|
Berne S.E.
| PHGN | End-of-day quote | |
|
OTC Markets
| PHGUF | Delayed | |
|
Deutsche Boerse AG
| PHGN | Delayed | |
|
Xetra
| PHGN | Delayed | |
|
CBOE
| 0QCO | Real-time | |
|
London S.E.
| 0QCO | Delayed | |
|
Boerse Muenchen
| PHGN | Real-time |
Last Transcript: Pharming Group N.V.
| 1 day | +0.11% | ||
| 1 week | -5.74% | ||
| 1 month | -10.15% | ||
| 3 months | -26.19% | ||
| 6 months | -38.13% | ||
| Current year | -37.78% |
| 1 week | 0.86 |  | 0.94 |
| 1 month | 0.86 | | 1 |
| Current year | 0.83 | | 1.82 |
| 1 year | 0.83 | | 1.82 |
| 3 years | 0.65 | | 1.82 |
| 5 years | 0.65 | | 1.82 |
| 10 years | 0.21 | | 1.82 |
| Manager | Title | Age | Since |
|---|---|---|---|
Kenneth Lynard
CEO | Chief Executive Officer | 58 | 2026-09-28 |
Leverne Marsh
CEO | Chief Executive Officer | - | 2026-09-28 |
Anurag Relan
CTO | Chief Tech/Sci/R&D Officer | 54 | 2021-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Barbara Yanni
BRD | Director/Board Member | 71 | 2020-12-10 |
Mark Pykett
BRD | Director/Board Member | 62 | 2020-12-10 |
| Director/Board Member | 60 | 2021-05-18 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 11/12/25 | Free | Director | 3,613 | 0.0005% | ||
| 10/23/25 | Sell | Chief Technology Officer | 337,500 | 0.0496% | ||
| 10/23/25 | Exercice | Compliance Officer | 85,000 | 0.0125% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.11% | -5.74% | -28.62% | -26.98% | 711M | |
| -2.33% | +0.53% | +51.65% | +115.42% | 1,056B | |
| -1.06% | -1.65% | +42.78% | +69.98% | 645B | |
| -0.65% | -1.32% | +12.98% | +75.49% | 465B | |
| -2.66% | -1.87% | +73.13% | +41.15% | 368B | |
| -0.06% | -3.88% | +34.32% | +39.39% | 335B | |
| -0.79% | +2.01% | +19.82% | +27.79% | 275B | |
| -1.19% | -1.21% | +9.82% | +10.61% | 255B | |
| -0.50% | +3.80% | +49.37% | +56.84% | 229B | |
| -1.47% | -1.53% | +34.28% | +98.89% | 188B | |
| Average | -0.75% | -0.74% | +29.95% | +50.86% | 381.65B | |
| Weighted average by Cap. | -1.02% | -0.23% | +39.90% | +71.37% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 383M 338M 320M 289M 544M 36.76B 551M 3.83B 1.47B 18.79B 1.44B 1.41B 60.24B | 417M 367M 348M 314M 592M 40.01B 600M 4.17B 1.6B 20.45B 1.57B 1.53B 65.57B |
| Net income | 22.11M 19.47M 18.45M 16.65M 31.39M 2.12B 31.8M 221M 84.94M 1.08B 83.03M 81.22M 3.47B | 33.62M 29.61M 28.05M 25.32M 47.73M 3.22B 48.35M 336M 129M 1.65B 126M 123M 5.28B |
| Net Debt | -46.69M -41.12M -38.96M -35.17M -66.28M -4.48B -67.14M -466M -179M -2.29B -175M -172M -7.34B | -62.12M -54.7M -51.83M -46.79M -88.18M -5.96B -89.32M -620M -239M -3.04B -233M -228M -9.76B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-30 | €0.8872 | +0.11% | 7,936,648 |
| 26-09-29 | €0.8862 | -3.67% | 15,705,407 |
| 26-09-28 | €0.9200 | -0.78% | 5,111,005 |
| 26-09-25 | €0.9272 | +1.60% | 7,283,828 |
| 26-09-24 | €0.9126 | -3.04% | 6,559,756 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PHARM Stock
Select your edition
All financial news and data tailored to specific country editions
